Q1 2018 Earnings Estimate for Charles River Laboratories Intl. Inc Issued By First Analysis (NYSE:CRL)

Charles River Laboratories Intl. Inc (NYSE:CRL) – Research analysts at First Analysis reduced their Q1 2018 EPS estimates for shares of Charles River Laboratories Intl. in a report issued on Monday, according to Zacks Investment Research. First Analysis analyst T. Van. Fleet now forecasts that the medical research company will earn $1.29 per share for the quarter, down from their prior estimate of $1.32. First Analysis also issued estimates for Charles River Laboratories Intl.’s Q2 2018 earnings at $1.43 EPS, Q3 2018 earnings at $1.38 EPS and FY2018 earnings at $5.50 EPS.

Other equities analysts have also issued research reports about the company. Argus initiated coverage on Charles River Laboratories Intl. in a research report on Wednesday, December 13th. They issued a “buy” rating and a $120.00 price target for the company. Zacks Investment Research lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Monday, November 13th. Robert W. Baird set a $117.00 price objective on Charles River Laboratories Intl. and gave the stock a “buy” rating in a research report on Monday, November 13th. Bank of America decreased their price objective on Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, November 10th. Finally, Jefferies Group raised their price objective on Charles River Laboratories Intl. from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $112.36.

Charles River Laboratories Intl. (NYSE CRL) traded down $1.79 during trading hours on Tuesday, hitting $108.06. The company had a trading volume of 483,951 shares, compared to its average volume of 341,206. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62. Charles River Laboratories Intl. has a fifty-two week low of $77.61 and a fifty-two week high of $119.05. The firm has a market cap of $5,120.00, a price-to-earnings ratio of 26.42, a price-to-earnings-growth ratio of 1.64 and a beta of 0.88.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.08. Charles River Laboratories Intl. had a return on equity of 26.58% and a net margin of 10.72%. The business had revenue of $464.23 million during the quarter, compared to analyst estimates of $458.93 million. During the same quarter last year, the company posted $1.18 EPS. Charles River Laboratories Intl.’s revenue for the quarter was up 9.0% on a year-over-year basis.

Institutional investors have recently made changes to their positions in the company. Lord Abbett & CO. LLC bought a new position in shares of Charles River Laboratories Intl. in the 2nd quarter valued at approximately $65,915,000. FMR LLC raised its stake in shares of Charles River Laboratories Intl. by 23.8% in the 2nd quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock valued at $311,458,000 after acquiring an additional 591,066 shares in the last quarter. Mackenzie Financial Corp raised its stake in shares of Charles River Laboratories Intl. by 81.7% in the 3rd quarter. Mackenzie Financial Corp now owns 928,796 shares of the medical research company’s stock valued at $100,329,000 after acquiring an additional 417,739 shares in the last quarter. TimesSquare Capital Management LLC bought a new position in shares of Charles River Laboratories Intl. in the 3rd quarter valued at approximately $35,182,000. Finally, FIL Ltd raised its stake in shares of Charles River Laboratories Intl. by 325.4% in the 2nd quarter. FIL Ltd now owns 417,465 shares of the medical research company’s stock valued at $42,227,000 after acquiring an additional 319,324 shares in the last quarter. Institutional investors and hedge funds own 95.80% of the company’s stock.

In other news, insider Bradley Nixon Scharfe sold 1,000,000 shares of Charles River Laboratories Intl. stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $0.27, for a total transaction of $270,000.00. Also, Director C Richard Reese sold 10,227 shares of Charles River Laboratories Intl. stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $102.40, for a total value of $1,047,244.80. Following the sale, the director now owns 51,444 shares of the company’s stock, valued at $5,267,865.60. The disclosure for this sale can be found here. Over the last quarter, insiders have bought 10,500 shares of company stock valued at $2,885 and have sold 1,064,673 shares valued at $2,876,056. 2.20% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Q1 2018 Earnings Estimate for Charles River Laboratories Intl. Inc Issued By First Analysis (NYSE:CRL)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/11/charles-river-laboratories-international-inc-crl-forecasted-to-post-q1-2018-earnings-of-1-29-per-share.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply